TABLE 4.
Observed SVR24 rate in the presence of baseline variants
| GT1a target | Variant | % SVR24a |
P valueb | |
|---|---|---|---|---|
| With variant | Without variant | |||
| NS3 | Q80K | 88 (78/89) | 94 (122/130) | 0.14 |
| D168A | 0 (0/1) | 92 (200/218) | 0.087 | |
| NS5A | M28T/V | 86 (12/14) | 92 (192/209) | 0.339 |
| Q30R | 100 (3/3) | 91 (201/220) | 1.0 | |
| L31V | 100 (1/1) | 91 (203/222) | 1.0 | |
| Y93C/N/H | 80 (4/5) | 92 (200/218) | 0.362 | |
| NS5B | S556G | 100 (7/7) | 92 (220/239) | 1.0 |
| C316Y | 50 (1/2) | 93 (226/244) | 0.149 | |
a
Data in parentheses represent the number of patients achieving SVR24/total number of patients who had a sequence available. Patients not achieving SVR24 for nonvirologic reasons, e.g., early discontinuations and missing SVR24 data, were excluded from this analysis.
b
P values were determined by the chi-square test.